

ROUND 19 BID PROSPECTUS 2017

CHRONIC CONDITION INTERVENTIONS
COOPERATIVE RESEARCH CENTRE



BID PROSPECTUS 2017

VISION

Minimising avoidable hospitalisations resulting from chronic conditions

AIMS

We will reduce the incidence and severity of complications associated with chronic illness and ageing by providing patients access to the right treatment, with the right product, at the right time.

MISSION

We will integrate industry with end users to transform the lives of people with chronic conditions and implement practical, hands on and cost-effective health care to lessen the burden on the Australian Health System.

CHRONIC CONDITION INTERVENTIONS CRC

PROBLEM:

The Wound Management Innovation CRC (WMI CRC) has achieved direct benefits for patients suffering from wounds, health professionals and industry partners.

A compelling body of research showed that early interventions and the application of research-based practice was essential to patient healing. However, wounds represent a late and urgent call to action for many other conditions associated with chronic illness and ageing.


Despite significant funding of chronic condition management strategies including the National Diabetes Services Scheme, the 2005 National Chronic Disease Strategy and the 2011 Chronic Disease Prevention and Service Improvement Fund, chronic wounds still cost Australia nearly \$3B a year.

Patients with a chronic wound offer a unique entry point to research why current approaches to managing chronic conditions are not protecting patients from disease progression and complications, and to develop

strategically targeted interventions and care pathways that address this significant unmet need.

Leveraging the WMI CRC's strong engagement with industry and end-user partners, the Chronic Condition Interventions CRC will lead to the provision of interventions to patients earlier and more effectively to intercept patient progression before chronic complications occur.

Ultimately, this new CRC will have a profound impact on the lives of patients, prevent hospitalisations and reduce health care costs from the growing burden of chronic health conditions.



DOING NOTHING FOR THESE PATIENTS IS NOT AN OPTION





CASE STUDY

Consider the case of a 65 year old male suffering diabetes mellitus who had a lower limb amputation for peripheral arterial disease. Following the amputation, he resided in a high care residential facility in a wheel chair. He only survived for 4 years.

In the 10 years prior to the amputation he suffered a series of chronic diabetic foot ulcers and had vascular surgery on 2 occasions. He was hospitalised for his foot and leg ulcers for a total of 183 days. He suffered from poor quality of life and had countless medical appointments, medications and medical devices. Conservatively, the cost of managing this patient during this period was more than \$850,000.

When this man first presented with a curable diabetic foot ulcer was the time to act. If he had received the right treatment with the right products at that time the amputation could have been prevented and the course of this man's health care journey dramatically altered. The research conducted in the CCI CRC and the translation of that research into primary care will dramatically change how the health care systems co-ordinate and deliver services and education to this individual.

The CCI CRC research will influence activity from the point of first treatment presentation and prevent or significantly delay the journey to an acute event such as this amputation. Through the research conducted and translated by the CCI CRC, patients such as this will not be hospitalised, will live a better and longer life with both lower limbs.

RESEARCH PROGRAMS

PROGRAM ONE

Industry Driven Clinical Research

Working closely with our Industry Growth Centre (MTP Connect) this research program will integrate industry partners and end users to ensure patients receive best practice treatment, with the best products at the earliest stage of presentation.

The CCI CRC will connect and foster relationships between end users such as aged care providers, community nursing and Primary Health Networks with Industry Partners to conduct high impact research projects, and feed back into industry product development portfolios.

Research projects will include clinical trials, product/ medical device/pharmaceutical evaluations, and technology development by joining our Industry Partners with patients and health professionals working on the frontline treating Australians living with chronic conditions.

Outcomes from this research will provide solutions to our end users, align MTP Industry Partner product development with end user needs and benefit patients by improving access to the best products, technologies and practices emerging and currently available.

PROGRAM TWO

Prevention and Early intervention Research


This program will conduct collaborative research projects that join industry and health care providers with researchers such as, exercise physiologists, nutritionists, health economists, psychiatrists, behavioural psychologists, medical educators and primary care practitioners.

For many conditions associated with chronic illness and ageing management strategies are not based around the development of new technologies or pharmaceuticals which may require long development times and large budgets.

Sustainable long term management can be implemented by providing our end users with clinical data relevant to their care setting, products and technologies already developed by our Industry Partners

(Research Program 1) and, crucially, strong health economic evidence to support decision making.

Research projects in this program will generate high quality data in primary health care settings by utilising the skills, experience and capacity of our researchers. Combined with health economic evidence, research project outcomes will inform evidence based best practice, develop new policies and pathways of care and drive change using clinical data and economic evidence.



RESEARCH PROGRAM 1

RESEARCH PROGRAM 2

RESEARCH PROGRAM 3

- IMPROVE QUALITY OF LIFE
- REDUCE AVOIDABLE HOSPITALISATIONS
- BENEFIT HEALTHCARE BUDGETS



Translation of CCI CRC research into primary care will **dramatically change how the health care systems co-ordinate and deliver services and education to individuals**

PROGRAM THREE Clinical Translation

This program will focus on translating the outcomes of Research Program 1 and 2 to ensure patients receive access to the right treatment, with the right product at the right time.

The Program will provide effective tools and technologies to Primary Health Networks, general practitioners, aged care providers and community nursing such as clinical decision-making algorithms and decision support tools, case management and care delivery pathways and access to products and technologies.

At a service delivery level the integration of best practice pathways, products and improved access to services will be achieved by developing new models of health care, improved coordination of existing health care and advancing telehealth technologies.

This program will also develop and use innovative education materials to empower health care professionals and consumers.

Education will include online, print, social media, face to face education and other digital education approaches.

The CCI CRC will leverage the Wound CRC's education networks and assets (Wound Healing Institute Australia www.whia.com.au and Diabetic Foot Australia www.diabeticfootaustralia.org), clinical services (Wound Innovations www.woundinnovations.com.au) and by adopting an already successful and validated approach will create more effective and efficient health models to empower Primary Health Care Networks, Aged Care Services, GP groups and Health Care Homes.

WHAT IS A CRC?

The Australian Government's Cooperative Research Centres (CRC) Programme supports industry-led collaborations between industry, researchers and the community. It's a proven model for linking researchers with industry to focus on research and development towards use and commercialisation.

It aims to:

- improve the competitiveness, productivity and sustainability of Australian industries, especially where Australia has a competitive strength
- deliver outcomes in line with government priorities
- encourage and enable small and medium enterprise (SME) participation in collaborative research
- foster high quality research to help solve industry specific problems through collaborative research partnerships between industry entities and research organisations.

CRC's are funded for up to 10 years to catalyse collaboration between industry research and community sectors to develop important new technologies, products and services.

CONNECTION WITH INDUSTRY GROWTH CENTRE

CCI CRC directly addresses two of the four objectives identified in the biotechnology and pharmaceutical sector Industry Growth Centre (MTP Connect) Sector Competitiveness Plan, specifically:

OBJECTIVE 1: Improving coordination and collaboration between research and industry

CCI CRC will catalyse engagement between industry and researchers (Research Program 1).

OBJECTIVE 2: Improving management and workforce skills

All CRC funded PhD Projects will involve direct participation with industry participants and mentorship. PhD students will undertake a graduate certificate relevant to their destination industry e.g. post-graduate training in research commercialisation. This deep industry engagement of students will also upskill academic research supervisors in collaborative approaches to industry research.

The CRC will fund projects that directly address the megatrends for the sector identified by MTP Connect including:

- ➔ work with governments and healthcare providers to make sure research priorities and new technologies improve population health outcomes in a more cost effective manner
- ➔ build advanced clinical product development systems that support consumer-driven decisions and consumer responsive products and services
- ➔ integrated care models including packaging products and devices as part of a broader care proposition, backed by evidence supporting health economic benefits

The CRC will align project funding to improve commercial outcomes by leveraging MTP Connects proposed guidelines for the allocation of research grants.


ALIGNMENT WITH GOVERNMENT PRIORITIES

The CCI CRC is directly aligned with the Australia Government's Science and Research Priorities in the area of Health - to build healthy and resilient communities throughout Australia by developing treatments, solutions and preventative strategies to improve physical and mental well-being and improve the efficiency and effectiveness of Australia's health care system.

The vision of CCI CRC is specifically targeted to address the number 1 Practical Challenge identified in these Priorities, that is better models of health care and services that improve outcomes, reduce disparities for disadvantaged and vulnerable groups, increase efficiency and provide greater value for a given expenditure.

CCI CRC will develop telemedicine approaches that will lead to better health outcomes for regional patients including indigenous people as outlined in Practical Challenge 3. CCI CRC will also support clinical research into technologies for individuals to manage their own health care (Practical Challenge 4),

CCI funded research will provide Partners with evidence and health economic impact analyses to address the 2017-2025 National Strategic Framework for Chronic Conditions, across all 3 Framework Objectives.



Efficient direction of medication and medical devices for this patient population **is a major challenge for Industry, End Users and the Australian healthcare system**

3^{of 4}

Practical challenges

AUSTRALIAN GOVERNMENT
SCIENCE AND RESEARCH
PRIORITIES 2015 - HEALTH

ALL 3

Framework Objectives

2017-2025 NATIONAL
STRATEGIC FRAMEWORK FOR
CHRONIC CONDITIONS

2^{of 4}

Sector Objectives

MTP CONNECT INDUSTRY
GROWTH CENTRE - SECTOR
COMPETITIVENESS PLAN 2016

“A focus on prevention can significantly reduce the volume and severity of chronic conditions and provide long-term cost savings and better health outcomes.

Strategies to effectively manage chronic conditions are equally important, to minimise multiple co-morbidities, complications and associated disabilities and to optimise quality of life.”

NATIONAL STRATEGIC FRAMEWORK FOR CHRONIC CONDITIONS MAY 2017

GOVERNANCE

The Participants in the CCI CRC will sign agreements with the Commonwealth Government and between Participants. CCI CRC will operate within the Commonwealth Guidelines utilising the governance structure successfully adopted by the WMI CRC.

This structure will ensure there is a low level of administration required for Participants and CCI CRC head office costs can be used efficiently.

The CCI CRC will be established as a company limited by Guarantee with the following key attributes:

- A Chair and Governing Board all of which are independent of Participants

- A CEO who is independent of Participants and of a suitable commercial background
- An unincorporated Joint Venture (UJV) will set out the relationship between the Participants
- The management company will be charged with managing the funding for the UJV and activities of the center approved by the Commonwealth.
- A constitutional ability to make all decisions that serve the interests of the organization, the Commonwealth and the Participants
- An Independent Research Advisory Committee will provide independent and expert advice regarding the quality and appropriateness of research proposals and projects.

JOINING AS A PARTICIPANT

The CRC will be an 8 year collaboration between medical and health focused industry partners, healthcare providers and organisations, government departments and agencies, health focused charities and peak bodies and research institutes.

CRC Participants will gain access to research funding to deliver research outputs that directly address Industry and End User needs, and more broadly benefit from the CRC Clinical Translation outputs including clinical care pathways and decision support tools.

Key benefits of participating in the CRC include

- Coordinated access to expert health care researchers to address sector wide issues
- Increased R&D capability through collaboration and public investment
- Potential eligibility for the Australian R&D taxation regime

- Partnering with Australia’s leading researchers, to deliver industry focused outcomes
- The total cost of the programme will be funded by cash and in-kind contributions from Participants and a cash Commonwealth grant. Funding rules require at least 50% of the overall resources being contributed by Participant Organisations, in the form of cash contributions and substantial in-kind contributions of personnel, equipment, products or services.
- The CRC will fund industry driven research projects, leverage research outcomes into clinical practice and fund a significant cohort of industry focused PhD and Masters students.

THE CRC IS ACTIVELY SEEKING PARTICIPANTS FOR AN 8 YEAR CRC SUBMISSION IN THE FOLLOWING AREAS:

MEDICAL TECHNOLOGY AND PHARMACEUTICAL ORGANISATIONS	Australian and international companies commercialising technologies, medical devices and consumables in the chronic health condition sector
	Small and medium Australian enterprises developing and commercialising innovative approaches to managing chronic health conditions
RESEARCH PROVIDERS	Universities and other research organizations
HEALTH CARE PROVIDERS	Community Nursing, Primary Health Care, GP clinics, Aged Care providers
HEALTH DEPARTMENTS AND NETWORKS	State Health Departments, Agencies and Primary Health Care Networks
REPRESENTATIVE BODIES	Chronic disease focused peak bodies and charities

BID TIMELINE

JUNE 2017

Initial research programme scoped, participant discussion leading to commitments.

JULY 3RD 2017

Participant declarations of intent due.

JULY 12TH 2017

Stage 1 application form submitted including declarations of intent from potential participants, a description of the research programmes, industry outcomes, governance, education and training programmes, value for money, governance and alignment with Industry Growth Centres.

SEPTEMBER 2017

Shortlisted bids announced and stage 2 application round opens.

NOVEMBER 2017

Stage 2 application including full business case submitted.

MARCH 2018

Outcomes announced.

JULY 2018

Successful CRC's commence, initial research projects funded.


THE BID TEAM

The CCI CRC bid is being prepared by the Wound Management Innovation Cooperative Research Centre team, including WMI CRC CEO, Dr Ian Griffiths, Special Initiatives Director Dr Anthony Dyer and Research and Development Director Dr Tamsin Terry.

The team has between them more than 45 years experience leading research bids, running research organisations and delivering healthcare outcomes.

PARTICIPANT APPLICATION PROCESS

1. Contact the bid team via +61 07 3088 6666 or research@woundcrc.com
2. Arrange a detailed discussion with the bid team to directly discuss the bid opportunity, benefits to your organisation and research themes
3. Provide a Participant declaration of intent by July 3rd 2017



BID TEAM

Dr Ian Griffiths
Dr Anthony Dyer
Dr Tamsin Terry

research@woundcrc.com

+61 7 3088 6666

PO BOX 2375
Toowong DC QLD 4066